Pub Date : 2024-10-29DOI: 10.1186/s43088-024-00569-8
Tran Xuan Ngoc Huy
Background
While often unrecognized, brucellosis, a significant zoonotic disease, silently endangers the health of mothers and children worldwide. This scoping review sheds light on transmission pathways, maternal–fetal consequences, and treatment hurdles, specifically considering maternal and child health concerns.
Method
To comprehensively grasp brucellosis in mothers and children, we systematically scoured electronic databases (DOAJ, Google Scholar, PubMed, and Semantic Scholar) for studies published after 2005. Our search included experimental studies (both randomized controlled clinical trials and quasi-experimental), analytical observations, descriptive reports, qualitative papers, and existing systematic reviews. All retrieved data were then charted and processed following Arksey and O'Malley's established framework for scoping reviews.
Result
Twenty-five studies spanning varied regions and methodologies met inclusion criteria. Key findings demonstrate that zoonotic brucellosis acquisition from livestock exposures among vulnerable maternal groups accounts for up to 70% of cases. Vertical transmission from mother to child during pregnancy, delivery, or breastfeeding was reported in 15–20% of cases. Substantial risks of miscarriage (25%), preterm birth (20%), hepatosplenomegaly (10%), febrile illness (30%), and possible long-term complications were documented. Treatment success rates using combination antibiotic therapy were reported to be as high as 98%, though emerging antibiotic resistance patterns challenge effective treatment, with 25% of Brucella isolates resistant to rifampin and 51% resistant to both trimethoprim-sulfamethoxazole and streptomycin.
Conclusion
This review reveals the alarming yet hidden toll brucellosis takes on maternal–fetal pairs and breastfeeding. In regions battling this endemic disease, tailored education, upgraded diagnostic tools, prompt antibiotic therapy, responsible antimicrobial stewardship, and One Health collaborations offer crucial pathways to shield mothers and children from its harmful consequences. Continued research will pave the way for even better solutions to alleviate this complex zoonosis, particularly for vulnerable populations.
{"title":"Exploring the impact of brucellosis on maternal and child health: transmission mechanisms, patient effects, and current trends in drug use and resistance: a scoping review","authors":"Tran Xuan Ngoc Huy","doi":"10.1186/s43088-024-00569-8","DOIUrl":"10.1186/s43088-024-00569-8","url":null,"abstract":"<div><h3>Background</h3><p>While often unrecognized, brucellosis, a significant zoonotic disease, silently endangers the health of mothers and children worldwide. This scoping review sheds light on transmission pathways, maternal–fetal consequences, and treatment hurdles, specifically considering maternal and child health concerns.</p><h3>Method</h3><p>To comprehensively grasp brucellosis in mothers and children, we systematically scoured electronic databases (DOAJ, Google Scholar, PubMed, and Semantic Scholar) for studies published after 2005. Our search included experimental studies (both randomized controlled clinical trials and quasi-experimental), analytical observations, descriptive reports, qualitative papers, and existing systematic reviews. All retrieved data were then charted and processed following Arksey and O'Malley's established framework for scoping reviews.</p><h3>Result</h3><p>Twenty-five studies spanning varied regions and methodologies met inclusion criteria. Key findings demonstrate that zoonotic brucellosis acquisition from livestock exposures among vulnerable maternal groups accounts for up to 70% of cases. Vertical transmission from mother to child during pregnancy, delivery, or breastfeeding was reported in 15–20% of cases. Substantial risks of miscarriage (25%), preterm birth (20%), hepatosplenomegaly (10%), febrile illness (30%), and possible long-term complications were documented. Treatment success rates using combination antibiotic therapy were reported to be as high as 98%, though emerging antibiotic resistance patterns challenge effective treatment, with 25% of Brucella isolates resistant to rifampin and 51% resistant to both trimethoprim-sulfamethoxazole and streptomycin.</p><h3>Conclusion</h3><p>This review reveals the alarming yet hidden toll brucellosis takes on maternal–fetal pairs and breastfeeding. In regions battling this endemic disease, tailored education, upgraded diagnostic tools, prompt antibiotic therapy, responsible antimicrobial stewardship, and One Health collaborations offer crucial pathways to shield mothers and children from its harmful consequences. Continued research will pave the way for even better solutions to alleviate this complex zoonosis, particularly for vulnerable populations.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"13 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-024-00569-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142540756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1186/s43088-024-00564-z
Hesham A. Mahran, Shawky M. Aboelhadid, Khaled M. Hassan
{"title":"Correction: Synthesis and efficacy of cinnamon oil formulations and their sustainable release against common house mosquito larvae","authors":"Hesham A. Mahran, Shawky M. Aboelhadid, Khaled M. Hassan","doi":"10.1186/s43088-024-00564-z","DOIUrl":"10.1186/s43088-024-00564-z","url":null,"abstract":"","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"13 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-024-00564-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-23DOI: 10.1186/s43088-024-00566-x
Doaa M. Anwar, Heidy Y. Hedeya, Sama H. Ghozlan, Basma M. Ewas, Sherine N. Khattab
<div><h3>Background</h3><p>Nanoparticle-mediated drug delivery aims to target specific cells, addressing the challenge that many drugs lack the necessary properties to reach their intended targets effectively. Lipid-based nanocarriers considered as a promising drug delivery due to their biocompatibility and ability to encapsulate various drugs. Surface modifications, including the attachment of polyethylene glycol for stability and the conjugation of targeting ligands (e.g., antibodies, peptides) for specific delivery, play a crucial role in enhancing the interaction of these nanocarriers with biological environments. These modifications improve cellular uptake and targeted delivery, thereby increasing therapeutic efficacy and reducing side effects. This review will explore various surface modification techniques and their impact on the performance of lipid nanocarriers in drug delivery.</p><h3>Main body</h3><p>Lipid-based nanodelivery platforms have garnered significant interest due to their notable characteristics, including their ability to accommodate high drug loads, reduced toxicity, improved bioavailability, and compatibility with biological systems, stability within the gastrointestinal environment, controlled release capabilities, streamlined scaling up processes, and simplified validation procedures. Targeted lipid-based nanocarriers represent a significant advancement over non-targeted counterparts in cancer therapy. Unlike non-targeted systems, which distribute drugs indiscriminately throughout the body, targeted lipid-based nanocarriers can be engineered with ligands or antibodies to specifically recognize and bind to tumor-associated markers, enabling precise drug delivery to cancer cells. This targeted approach enhances therapeutic efficacy while minimizing adverse effects on healthy tissues, thereby offering a promising strategy for improving the outcomes of cancer treatment.</p><h3>Conclusion</h3><p>The authors in this review provide an overview of preclinical research on diverse lipid-based nanocarriers, such as liposomes, solid lipid nanocarriers, and lipid polymer hybrid nanoparticles. The customization of these carriers using various surface modifiers is discussed, including folic Acid, peptides, polysaccharides, transferrin, and antibodies. Surface-modified nanocarriers offer regulated discharge, improved penetration capability, and precise drug conveyance. This work compiles recent instances of emerging surface-modified lipid-based nanocarrier systems and their applications, sourced from existing literature. Novel approaches to surface engineering of these nanocarriers, aimed at enhancing their specificity and efficacy in targeted drug delivery, were discussed. Key advancements in this field, such as improved targeting mechanisms and significant therapeutic outcomes demonstrated in preclinical studies, were highlighted. Additionally, critical gaps that require attention include long-term stability, biocompatibility, scalabl
{"title":"Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment","authors":"Doaa M. Anwar, Heidy Y. Hedeya, Sama H. Ghozlan, Basma M. Ewas, Sherine N. Khattab","doi":"10.1186/s43088-024-00566-x","DOIUrl":"10.1186/s43088-024-00566-x","url":null,"abstract":"<div><h3>Background</h3><p>Nanoparticle-mediated drug delivery aims to target specific cells, addressing the challenge that many drugs lack the necessary properties to reach their intended targets effectively. Lipid-based nanocarriers considered as a promising drug delivery due to their biocompatibility and ability to encapsulate various drugs. Surface modifications, including the attachment of polyethylene glycol for stability and the conjugation of targeting ligands (e.g., antibodies, peptides) for specific delivery, play a crucial role in enhancing the interaction of these nanocarriers with biological environments. These modifications improve cellular uptake and targeted delivery, thereby increasing therapeutic efficacy and reducing side effects. This review will explore various surface modification techniques and their impact on the performance of lipid nanocarriers in drug delivery.</p><h3>Main body</h3><p>Lipid-based nanodelivery platforms have garnered significant interest due to their notable characteristics, including their ability to accommodate high drug loads, reduced toxicity, improved bioavailability, and compatibility with biological systems, stability within the gastrointestinal environment, controlled release capabilities, streamlined scaling up processes, and simplified validation procedures. Targeted lipid-based nanocarriers represent a significant advancement over non-targeted counterparts in cancer therapy. Unlike non-targeted systems, which distribute drugs indiscriminately throughout the body, targeted lipid-based nanocarriers can be engineered with ligands or antibodies to specifically recognize and bind to tumor-associated markers, enabling precise drug delivery to cancer cells. This targeted approach enhances therapeutic efficacy while minimizing adverse effects on healthy tissues, thereby offering a promising strategy for improving the outcomes of cancer treatment.</p><h3>Conclusion</h3><p>The authors in this review provide an overview of preclinical research on diverse lipid-based nanocarriers, such as liposomes, solid lipid nanocarriers, and lipid polymer hybrid nanoparticles. The customization of these carriers using various surface modifiers is discussed, including folic Acid, peptides, polysaccharides, transferrin, and antibodies. Surface-modified nanocarriers offer regulated discharge, improved penetration capability, and precise drug conveyance. This work compiles recent instances of emerging surface-modified lipid-based nanocarrier systems and their applications, sourced from existing literature. Novel approaches to surface engineering of these nanocarriers, aimed at enhancing their specificity and efficacy in targeted drug delivery, were discussed. Key advancements in this field, such as improved targeting mechanisms and significant therapeutic outcomes demonstrated in preclinical studies, were highlighted. Additionally, critical gaps that require attention include long-term stability, biocompatibility, scalabl","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"13 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-024-00566-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142518780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-23DOI: 10.1186/s43088-024-00567-w
Indira Mikkili, Jagadish Kumar Suluvoy, Jesse Joel Thathapudi, Krupanidhi Srirama
{"title":"Correction: Synergistic strategies for cancer treatment: leveraging natural products, drug repurposing and molecular targets for integrated therapy","authors":"Indira Mikkili, Jagadish Kumar Suluvoy, Jesse Joel Thathapudi, Krupanidhi Srirama","doi":"10.1186/s43088-024-00567-w","DOIUrl":"10.1186/s43088-024-00567-w","url":null,"abstract":"","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"13 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-024-00567-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142518514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-10DOI: 10.1186/s43088-024-00538-1
Miao Sun, Like Tang, Xiaofu Yang, Jingyi Lu, Huihui He, Jun Lin, Yong He, Mengfei Yu
Background
The deformation of oral and maxillofacial region leads to not only the damage of morphology and function, but also a series of aesthetic and psychological problems, severely affecting the quality of life of patients. Oral tissue engineering refers to developing biomaterials for repair or regeneration, with the application of tissue engineering technologies. This has become an area of increasing prominence. Current biologically inert materials are insufficient to fulfill clinical requirements. Therefore, tissue-engineered biomaterials with bioactive, even bionic properties are desperately needed.
Main body
The complexity of the anatomy and the diversity of tissue types of oral and maxillofacial region pose great challenges to the regeneration, in the aspects of both biomaterials and manufacturing technologies. Biomaterials in clinical practice or research have evolved from natural materials to synthetic materials, from homogeneous materials to multiple composite materials. And now composite materials have increasingly demonstrated their advantages in terms of physicochemical and biological properties over conventional materials. In terms of manufacturing, traditional coating, sintering, and milling technologies can no longer satisfy the requirements for high-precision bionic structures of oral-tissue-engineering biomaterials. Scientists have turned to biofabrication technologies such as microfluidics and additive manufacturing.
Short conclusion
This review aims to summarize the noteworthy advancements made in biomaterials of oral tissue engineering. We outlined the current biomaterials and manufacturing technologies and focused on various applications of these materials that may be connected to clinical treatment and research. We also suggested the future direction of development for biomaterials in oral tissue engineering. In future, biomaterials characterized by precision, functionalization, and individualization will be manufactured through digital, microfluidic, and 3D printing technologies.